Idec deal

IDPH (San Diego) will develop a new Primatized antibody directed at the B7 marker, which is present on certain cells of the immune system, under an agreement with Mitsubishi Kasei Corp (Tokyo).

B7 appears on the surface of antigen-presenting cells and is involved in their interaction with T cells in triggering a cascade of immune system responses. IDPH said the antibody may be useful in the treatment of systemic lupus erythematosus, idiopathic thrombocytopenic purpura, transplant rejection and other immune system diseases. ...